Erratum for Lee and Swain, J Clin Oncol 24 (10) 1633-1642.

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                            What's this?

ERRATUM

In Table 1 and Table 2, incorrect data sets were given for the number and percentage of patients with peripheral neuropathy. In Table 3, incorrect references were cited. The corrected version of each table is reprinted below in its entirety.

In the References section, reference 3 was given as:

"O’Shaughnessy J, Tjulandin S, Davidson N, et al: ABI-007 (ABRAXANE), a nanoparticle albuminbound (nab) paclitaxel demonstrates superior efficacy vs taxol in MBC: A phase III trial. 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003 (abstr 44)"

While it should have read:

Nyman DW, Campbell KJ, Hersh E, et al: Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785-7793, 2005"

The online version has been corrected in departure from the print.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                            What's this?